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Purpose. The goal of this review is to present current indications, injectable agents, techniques, success rates, complications, and
potential future applications of endoscopic treatment for vesicoureteral reﬂux (VUR) in children. Materials and Methods.T h e
endoscopic method currently achieving one of the highest success rates is the double hydrodistention-implantation technique
(HIT). This method employs dextranomer/hyaluronic acid copolymer, which has been used in pediatric urology for over 10 years
and may be at present the ﬁrst choice injectable agent due to its safety and eﬃcacy. Results. While most contemporary series
report cure rates of greater than 85% for primary VUR, success rates of complicated cases of VUR may be, depending on the case,
signiﬁcantly lower. Endoscopic treatment oﬀers major advantages to patients while avoiding potentially complicated open surgery.
As the HIT method continues to be applied to complex cases of VUR and more outcome data become available, the indication for
endoscopic treatment may exceed the scope of primary VUR. Conclusions. Endoscopic injection is emerging as the treatment of
choice for VUR in children.
Copyright © 2008 Wolfgang H. Cerwinka et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Vesicoureteral reﬂux (VUR) is diagnosed in approximately
1% of children and promotes pyelonephritis, which may
lead to renal scarring and hypertension [1]. VUR is one
of many treatable risk factors (e.g., dysfunctional elim-
ination) in the development of urinary tract infection
(UTI). Treatment intends to prevent pyelonephritis and to
preserve renal function and most children diagnosed with
VUR receive antibiotic prophylaxis regardless of VUR grade
[2]. Surgical management is indicated in cases of break-
through UTIs and/or persistence of VUR and comprises
ureteral reimplantation and endoscopic injection. Since the
introduction of endoscopic treatment for VUR in 1981 and
its ﬁrst clinical application in 1984 as subureteric Teﬂon
injection (STING), injection techniques, injectable agents,
and consequently treatment success rates have considerably
improved [3–6]. Endoscopic treatment not only approaches
success rates of open ureteral reimplantation but oﬀers
also signiﬁcant advantages to patients and parents such as
outpatient surgery, lower morbidity (e.g., pain, scar), fewer
complications, and reduced cost. Consequently, a major shift
from reimplantations toward injection treatments has been
observed over the last few years (Figure 1).
The purpose of this review is to summarize current
indications, injectable agents, techniques, successrates, com-
plications, and potential future applications of endoscopic
treatment for VUR.
2. MATERIALS AND METHODS
2.1. Goalsoftreatment
There is little evidence that antireﬂux surgery of any means
decreases the incidence of renal scarring or end-stage renal
disease. Worthwhile goals of treatment are to prevent UTIs,
particularly febrile UTIs, to avoid long-term antibiotic use,
and to lessen the need for distressing voiding cystourethro-
graphies (VCUG) and radiation exposure. Proponents of
the endoscopic approach will argue that decreasing the
incidence of UTI is the main goal of therapy. Recurrence,
while possible, may occur in the absence of symptoms and2 Advances in Urology
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Figure 1: Trend of surgical treatment for VUR at Children’s
Healthcare of Atlanta from 2000 to 2005.
be viewed as subclinical, similar to an individual with VUR
diagnosed after a sibling screen or for fetal hydronephrosis.
Proponents of the open surgical approach will argue that
ureteral reimplantation provides a permanent cure of VUR
and is worth the increased morbidity to achieve this goal. In
terms of reducing the risk of UTI, endoscopic treatment may
achieve this goal as well or better than open surgery [7–9].
2.2. Indications
The indications for ureteral reimplantation and endoscopic
treatment are with few exceptions identical and comprise
recurrent UTIs despite antibiotic prophylaxis, persistent
VUR after a period of observation (>2y e a r s ) ,p o o rc o m -
pliance with antibiotic prophylaxis, and new renal scarring.
When parents are counseled regarding surgical options, a
signiﬁcant preference for endoscopic treatment is apparent
[10, 11]. Endoscopic injection has more frequently been
employed for primary rather than for complex VUR (i.e.,
VUR associated with functional or anatomical abnormalities
such as neurogenic bladder or ectopic or megaureters).
Avoidance of endoscopic treatment for complex VUR is
due to a paucity of supportive clinical data and the current
view that bladder dysfunction and structural defects of the
ureterovesical junction necessitate ureteral reimplantation.
Endoscopic treatment is Food and Drug Administration
(FDA)-approved for VUR grades II to IV and for cases of
initial endoscopic treatment failure, however it has been
applied to all VUR scenarios. While open ureteral reimplan-
tation is the treatment of choice for failed injection therapy,
endoscopic treatment has been successfully employed after
failed ureteral reimplantation [12–14]. In general, endo-
scopic treatment is emerging as the treatment modality of
choice for VUR whereas ureteral reimplantation remains
reserved for cases of failed injection therapy, signiﬁcant
anatomicalabnormalities(e.g.,largeparaureteraldiverticula,
ectopic ureters, megaureters), and surgeon’s or parents’
preference.
2.3. Injectableagents
Numerous injectable bulking materials have been utilized
and abandoned over time in search for the ideal agent, which
should be nonimmunogenic, noncarcinogenic, biocompat-
ible, and biodegradable. Teﬂon, the ﬁrst bulking material
used for the treatment of VUR, was abandoned in pediatric
urology in the USA because of the material’s propensity
to migrate to distant organs and to form granulomas;
however, carcinogenesis of Teﬂon has not been reported
[15–17]. Silicone also demonstrates distant migration and
granuloma formation. Its carcinogenic potential has been
controversial but is most likely unsubstantiated [18, 19].
Glutaraldehyde cross-linked bovine collagen demonstrates a
lower degree of absorption as compared to native collagen
andcancauseallergicreactionseveninpatientswithnegative
skin test [20]. Several new bulking agents are currently under
investigation, such as inorganic materials and autologous
tissue. The latter is nonimmunogenic, however, cell harvest
and/or cell culture are time-consuming and expensive.
Dextranomer/hyaluronic acid copolymer (Deﬂux, Q-Med
Scandinavia Inc., Uppsala, Sweden) is easy to inject, is
biodegradable with stable implant volume, and its relatively
large particle size prevents distant migration [21, 22]. It has
been used as injectable material in pediatric urology for over
10 years and is currently the ﬁrst-choice injectable agent due
to its safety and eﬃcacy. Deﬂux implants in animal tissue
were shown to undergo time-dependent histopathological
changes. The initial phase was dominated by an ingrowth
of granulation tissue, a foreign-body giant-cell reaction, and
the formation of a surrounding capsule. In the later phase,
cellular elements were largely replaced by a collagen-rich
matrix,whereasthecapsuleremainedunchanged[21].These
ﬁndings were conﬁrmed in patients who experienced failed
endoscopic injection and proceeded to ureteral reimplan-
tation [22]. In our experience, explanted Deﬂux appears
essentially unchanged up to 4 years after implantation.
Besides biological properties, cost of bulking agents, and
surgeon’s experience, the choice may ultimately depend on
approval by administrative agencies, such as the European
Medicines Agency or the FDA.
2.4. Technique
The endoscopic method currently achieving one of the high-
est success rates is the double hydrodistention-implantation
technique (HIT). Cystoscopy is performed with a pediatric
cystoscope equipped with an oﬀ-set lens. An oﬀ-set lens
permits direct passage of the needle in line with the ureter
without bending the needle. The bladder is ﬁlled to less
than half capacity to permit visualization of the ureter
and avoid tension within the submucosal layer of the
ureter secondary to overdistention. Hydrodistention (HD)
is performed with the tip of the cystoscope placed at the
ureteral oriﬁce (UO), a pressured stream achieved by placing
the irrigation bag approximately 1 meter above the bladder
on full ﬂow. HD of the distal ureter serves two purposes:
it allows visualization of the intraureteral injection site and
assessment of treatment progress (i.e., ureteral coaptation).Wolfgang H. Cerwinka et al. 3
The needle is passed into the UO and inserted at the mid
ureteral tunnel at the 6 o’clock position. Suﬃcient bulking
agent is injected to produce a bulge, which initially coapts
the detrusor tunnel, while a second implant within the
most distal intramural tunnel leads to coaptation of the UO
(approximately 1–1.5mL). Rarely, if the two intraureteric
submucosal injections (double-HIT method) fail to coapt
the ureter, a classic STING or a supraureteric injection
is needed to achieve coaptation. The latter two injection
sites are used more commonly in complex or redo cases
(Figure 2). HD is performed after each injection to monitor
treatment progress; when HD ceases to dilate the UO,
appropriatecoaptationhasbeenachieved.Atourinstitution,
all procedures are performed on an outpatient basis and all
patients receive preoperative antibiotic prophylaxis, which
is continued until resolution of VUR has been conﬁrmed.
Radiographic success is deﬁned as grade 0 VUR on a
postoperative VCUG, from 1 to 3 months after a single
treatment. Patients are then followed clinically on an annual
basis to determine clinical success and recurrence.
We have shown that the Deﬂux bleb size, determined by
ultrasound, correlates with treatment success; a measured
volume higher than 25% of the injected volume using the
HIT method will result in a 90% cure and 95% using
the double HIT method [23, 24]. Consequently, as part
of a prospective clinical trial we are evaluating bladder
ultrasounds from 4 to 6 weeks after endoscopic injection
with measurement of the Deﬂux bleb. If the retained volume
is >25%, antibiotics will be discontinued, no VCUG will
be obtained until 1 year, and the patient will be followed
clinically. An earlier VCUG will be obtained for volumes
<25% or if clinically indicated. This protocol allows for the
identiﬁcation of clinically signiﬁcant VUR and will evaluate
the longer-term success rate. If the long-term VCUGs show
favorable results and/or if patients do well clinically, the
postoperative VCUG will be excluded in the future.
3. RESULTS AND DISCUSSION
3.1. Successrates
Outcome of endoscopic treatment for VUR has been evalu-
ated in several large series (Table 1). Most studies included
both, primary and complicated cases of VUR. Interpretation
of and comparison among these studies are confounded by
diﬀerent inclusion criteria (e.g., with or without complex
VUR, grade I, grade V), varying lengths of follow-up,
deﬁnitions of success, and single versus multiple injections.
Nevertheless, most current series report cure rates of greater
than 85%. Age, gender, and bilaterality of VUR have not
been shown to predict treatment outcome. While the STING
technique yields lower success rates with higher grades of
VUR, the HIT method achieves similar outcomes across all
VUR grades up to grade V [5]. Endoscopic treatment of
complicated VUR has been evaluated in smaller series and
success rates vary signiﬁcantly depending on the associated
pathologies (Table 2). In general, cure rates for complex
cases of VUR are lower than for primary VUR. Treatment
of VUR associated with neurogenic bladder was shown
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Figure2:Needleplacementalgorithmfortheendoscopictreatment
of VUR. Sites 1 and 2 comprise the double-HIT method, while site
3 (STING) is rarely used.
to yield acceptable outcome whereas voiding dysfunction
was a signiﬁcant predictor of treatment failure [13, 25].
Endoscopic injection has been successfully employed in
patients who either failed ureteral reimplantation or initial
injection [13, 14, 26]. Injection after failed reimplantion
or second injection will be curative in most instances
whereas a third injection has been shown to be far less
successful [27, 28]. Reﬂuxing ureters of transplanted kidneys
in symptomatic patients may be treated endoscopically.
Although this approach is curative in only half the cases,
yet it represents an attractive alternative to open surgery
in the setting of immune compromise and reduced wound
healing properties [29]. VUR associated with anatomical
abnormalities, previously thought to be contraindications
forendoscopictreatment,wasrecentlyshowntobeamenable
to injection treatment [30–32].
There are many factors that may aﬀect the success of the
procedure. Preoperative (i.e., patient selection), intraoper-
ative (i.e., injection technique), and postoperative variables
have been shown to correlate with treatment outcome
(Table 3). Postoperatively, failures may result from Deﬂux
displacement (implant migration), disruption (mucosal
breach), or dissolution (decrease in implant volume).
3.2. Advantages
In comparison to ureteral reimplantation, endoscopic VUR
treatment oﬀers major advantages to patients and parents.
The procedure generally lasts less than 15 minutes and is
performed on an outpatient basis. While cure rates are
approaching those of open ureteral reimplantation, signif-
icant complications are rare. Endoscopic treatment entails
greater patient convenience, lower morbidity (e.g., pain,
abdominal scar), and reduced cost [43, 44]. Consequently,
a signiﬁcant parental preference for endoscopic treatment
is evident [10, 11]. A recent study demonstrated that both,
patients and parents viewed injection therapy as the least
bothersome aspect of VUR treatment followed by antibiotic
prophylaxis and VCUG [8].4 Advances in Urology
Table 1: Success rates of endoscopic treatment for primary VUR. Meta-analysis by Elder JS et al. 2006 summarizes results until 2003. More
recent series are listed below. Initial success after one treatment and ﬁnal success after two or more treatments.
Reference Bulking agent Injected volume Ureters Follow-up Success
Initial Final
Elder et al. 2006 [27] Various 0.2–1.7 mL 8101 variable 76% 85%
Capozza et al. 2004 [33] Various 0.2–2.2 mL 1694 12–204 months 77%
Kirsch et al. 2004 [5] Dx/HA 0.5–1.5 mL 119 3–12 months 92%
Kirsch et al. 2006 [34] Dx/HA 0.8–2.0 mL 139 3–18 months 93%
Van Capelle et al. 2004 [35] PDMS 0.2–2 mL 311 3–110 months 75%
Kajbafzadeh et al. 2006 [36] Ca hydroxylapatite 0.4–0.6 mL 364 6 months 69%
Yu and Roth 2006 [6] Dx/HA 1 mL 162 2–26 months 87% 93%
Puri et al. 2006 [37] Dx/HA 0.2–1.5 mL 1101 3–46 months 87% 96%
Lorenzo et al. 2006 [38] PDMS 351 72 months 72%
Pinto et al. 2006 [39] Dx/HA 86 3 months 84%
Table 2: Success rates of endoscopic treatment for complex VUR.
Reference Pathology Bulking agent Injected volume Ureters Follow-Up Success
Perez-Brayﬁeld et al. 2004 [13] Neurogenic bladder Dx/HA 0.4–2.0 (1.1) 9 3 months 78%
Capozza et al. 2002 [25] Voiding dysfunction Dx/HA 3–6 months 49%
Elmore et al. 2006 [26] Failed initial injection Dx/HA 1.0–1.5 53 3 months 89%
Perez-Brayﬁeld et al. 2004 [13] Failed reimplantation Dx/HA 0.4–2.0 (1.1) 19 3 months 88%
Kitchens et al. 2006 [14] Failed reimplantation Dx/HA 0.7–3.8 (0.8) 20 19 months 83%
Campbell et al. 2006 [29] Renal transplantation Dx/HA 11 55%
Molitierno et al. 2007 [30] Duplicated ureter Dx/HA 0.8–2.8 (1.4) 63 1–3 months 85%
Cerwinka et al. 2007 [31] Paraureteral diverticulum Dx/HA 0.8–1.8 (1.2) 20 6.6 months 81%
Chertin et al. 2007 [32] Ureterocele Various 44 1–21 months 91%
3.3. Complications
The most common complications following endoscopic
treatment of VUR are new contralateral VUR (2.3–17.3%)
and treatment failure [35, 38]. Less than 4% of children
complain of ﬂank pain or emesis several hours after the
procedureandallrespondtoanalgesics[5].Grosshematuria,
urinary retention, or febrile UTIs have not been observed.
The most signiﬁcant potential complication of endoscopic
treatment for VUR includes a 0.6% risk of ureteral obstruc-
tion [45]. Our obstruction rate is 4 ureters (2 patients) in
over 1200 ureteral injections, or <0.3%. A 7-month old boy
with bilateral grade V VUR and spina biﬁda developed acute
renalfailureandhadbilateralureteralstentsplaced.ASTING
technique using 0.7mL was utilized. A postoperative VCUG
after stent removal showed bilateral grade V VUR and a
vesicostomy was performed. Interestingly, no VUR was seen
at the time of bladder augmentation 5 years later. A 6-year
old girl developed bilateral ureteral obstruction after HIT
using 1.1mL and 0.7mL. Bilateral nephrostomy tubes were
placed and removed 6 weeks later after a normal antegrade
study. The VCUG did not show any evidence of VUR and no
further treatment was required.
Factors that may increase the risk of obstruction include
bladder dysfunction and markedly dilated ureters. Patients
withrecurrentVURoftenremainasymptomaticandwithout
risk factors for pyelonephritis such as young age, voiding
dysfunction, or signiﬁcant history of UTIs may be taken oﬀ
antibiotic prophylaxis [46]. Febrile UTIs after radiographi-
cally successful endoscopic treatment warrant evaluation for
recurrent VUR.
3.4. Potentialfutureapplications
As endoscopic treatment continues to be applied to more
complex cases of VUR and outcome data become available,
the indication for endoscopic treatment may exceed the
scope of primary VUR. In the USA, for example, duplex
ureters are no longer considered a contraindication for
endoscopic treatment with Deﬂux by the FDA. Outcome
analysis of complex cases of VUR will aid in preoperative
counseling and patient selection and paired with proper
technique further improve success rates of endoscopic
VUR treatment. As adults with recurrent pyelonephritis are
more consistently evaluated for VUR, a patient population
with distinct requirements and disease characteristics mayWolfgang H. Cerwinka et al. 5
Table 3: Variables aﬀecting the outcome of endoscopic treatment of VUR with Deﬂux. Overall success for patients/ureters.
Reference Bulking agent Patients/Ureters Mean age Overall success Predictors of success Not predictive
Lavelle et al. 2005 [40] Dx/HA 52/80 7.6 years 71%/80% Volcano: present 87% Voiding dysfunction
absent 53% VUR grade
Injected volume
Yucel et al. 2007 [41] Dx/HA 168/259 4.2 years 82%/86% Volcano: present 87% Voiding dysfunction
absent 36% Laterality
Volume: <0.5mL success
>0.5mL failure
VUR grade
Routh et al. 2007 [42] Dx/HA 301/453 5.5 years 66%/72% VUR grade
Surgeon
emerge. Finally, once more accurate predictors of VUR res-
olution/persistence become available, endoscopic treatment
may be more frequently used as the primary treatment in
patients with low probability of VUR resolution.
4. CONCLUSIONS
Endoscopic treatment of VUR oﬀers signiﬁcant advantages
to patients and avoids potentially complicated open surgery.
While success of endoscopic treatment for primary VUR
approaches that of ureteral reimplantation, it is acceptable in
complex cases of VUR. Consequently, endoscopic injection
has assumed the role of ﬁrst-line VUR treatment whereas
ureteral reimplantation remains reserved for cases of failed
injection therapy or signiﬁcant anatomical abnormalities.
The development of new injectable agents in combination
with the improvement of endoscopic techniques will con-
tinue to strengthen the role of endoscopic treatment for
VUR.
ABBREVIATIONS
VUR: Vesicoureteral reﬂux
UTI: Urinary tract infection
STING: Subureteric Teﬂon injection
VCUG: Voiding cystourethrography
FDA: Food and Drug Administration
HIT: Hydrodistention Implantation Technique
HD: Hydrodistention
UO: Ureteral oriﬁce.
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